M Luo1,2, Y Ji3, Y Luo1, R Li1, W P Fay3,4,5, J Wu1. 1. Drug Discovery Research Center, Southwest Medical University, Luzhou, Sichuan, China. 2. Laboratory for Cardiovascular Pharmacology of the Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. 3. Department of Medicine, University of Missouri School of Medicine, Columbia, MO, USA. 4. Department of Medical Pharmacology & Physiology, University of Missouri School of Medicine, Columbia, MO, USA. 5. Research Service, Harry S. Truman Memorial Veterans Hospital, Columbia, MO, USA.
Abstract
Essentials Vitronectin (VN) is produced by smooth muscle cells (SMCs) and promotes neointima formation. We studied the regulation of vascular VN expression by plasminogen activator inhibitor-1 (PAI-1). PAI-1 stimulates VN gene expression in SMCs by binding LDL receptor-related protein 1. Stimulation of VN gene expression may be a mechanism by which PAI-1 controls vascular remodeling. SUMMARY: Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis. However, the molecular regulation of vascular VN expression is poorly defined. Given the overlapping expression profiles and functions of VN and plasminogen activator inhibitor (PAI)-1, we hypothesized that PAI-1 regulates vascular VN expression. Objectives To determine whether PAI-1 regulates VN expression in SMCs and in vivo. Methods The effects of genetic alterations in PAI-1 expression, pharmacologic PAI-1 inhibition and recombinant PAI-1 on SMC VN expression were studied, and vascular VN expression in wild-type (WT) and PAI-1-deficient mice was assessed. Results VN expression was significantly lower in PAI-1-deficient SMCs and significantly increased in PAI-1-overexpressing SMCs. PAI-1 small interfering RNA and pharmacologic PAI-1 inhibition significantly decreased SMC VN expression. Recombinant PAI-1 stimulated VN expression by binding LDL receptor-related protein-1 (LRP1), but another LRP1 ligand, α2 -macroglobulin, did not. As compared with WT controls, carotid artery VN expression was significantly lower in PAI-1-deficient mice and significantly higher in PAI-1-transgenic mice. In a vein graft (VG) model of intimal hyperplasia, VN expression was significantly attenuated in PAI-1-deficient VGs as compared with WT controls. The plasma VN concentration was significantly decreased in PAI-1-deficient mice versus WT controls at 4 weeks, but not at 5 days or 8 weeks, after surgery. Conclusions PAI-1 stimulates SMC VN expression by binding LRP1, and controls vascular VN expression in vivo. Autocrine regulation of vascular VN expression by PAI-1 may play important roles in vascular homeostasis and pathologic vascular remodeling.
EssentialsVitronectin (VN) is produced by smooth muscle cells (SMCs) and promotes neointima formation. We studied the regulation of vascular VN expression by plasminogen activator inhibitor-1 (PAI-1). PAI-1 stimulates VN gene expression in SMCs by binding LDL receptor-related protein 1. Stimulation of VN gene expression may be a mechanism by which PAI-1 controls vascular remodeling. SUMMARY: Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis. However, the molecular regulation of vascular VN expression is poorly defined. Given the overlapping expression profiles and functions of VN and plasminogen activator inhibitor (PAI)-1, we hypothesized that PAI-1 regulates vascular VN expression. Objectives To determine whether PAI-1 regulates VN expression in SMCs and in vivo. Methods The effects of genetic alterations in PAI-1 expression, pharmacologic PAI-1 inhibition and recombinant PAI-1 on SMC VN expression were studied, and vascular VN expression in wild-type (WT) and PAI-1-deficientmice was assessed. Results VN expression was significantly lower in PAI-1-deficient SMCs and significantly increased in PAI-1-overexpressing SMCs. PAI-1 small interfering RNA and pharmacologic PAI-1 inhibition significantly decreased SMC VN expression. Recombinant PAI-1 stimulated VN expression by binding LDL receptor-related protein-1 (LRP1), but another LRP1 ligand, α2 -macroglobulin, did not. As compared with WT controls, carotid artery VN expression was significantly lower in PAI-1-deficientmice and significantly higher in PAI-1-transgenic mice. In a vein graft (VG) model of intimal hyperplasia, VN expression was significantly attenuated in PAI-1-deficient VGs as compared with WT controls. The plasma VN concentration was significantly decreased in PAI-1-deficientmice versus WT controls at 4 weeks, but not at 5 days or 8 weeks, after surgery. Conclusions PAI-1 stimulates SMC VN expression by binding LRP1, and controls vascular VN expression in vivo. Autocrine regulation of vascular VN expression by PAI-1 may play important roles in vascular homeostasis and pathologic vascular remodeling.
Authors: Yan Ji; Tammy L Strawn; Elizabeth A Grunz; Meredith J Stevenson; Alexander W Lohman; Daniel A Lawrence; William P Fay Journal: Arterioscler Thromb Vasc Biol Date: 2011-05-12 Impact factor: 8.311
Authors: P Dufourcq; H Louis; C Moreau; D Daret; M R Boisseau; J M Lamazière; J Bonnet Journal: Arterioscler Thromb Vasc Biol Date: 1998-02 Impact factor: 8.311
Authors: I Mikhailenko; F D Battey; M Migliorini; J F Ruiz; K Argraves; M Moayeri; D K Strickland Journal: J Biol Chem Date: 2001-08-15 Impact factor: 5.157
Authors: Yan Ji; Zhen Weng; Philip Fish; Neha Goyal; Mao Luo; Samantha P Myears; Tammy L Strawn; Bysani Chandrasekar; Jianbo Wu; William P Fay Journal: Arterioscler Thromb Vasc Biol Date: 2016-09-22 Impact factor: 8.311
Authors: J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff Journal: Proc Natl Acad Sci U S A Date: 1992-08-01 Impact factor: 11.205
Authors: Hassan Elokdah; Magid Abou-Gharbia; James K Hennan; Geraldine McFarlane; Cheryl P Mugford; Girija Krishnamurthy; David L Crandall Journal: J Med Chem Date: 2004-07-01 Impact factor: 7.446
Authors: Daniel H Katz; Usman A Tahir; Alexander G Bick; Akhil Pampana; Debby Ngo; Mark D Benson; Zhi Yu; Jeremy M Robbins; Zsu-Zsu Chen; Daniel E Cruz; Shuliang Deng; Laurie Farrell; Sumita Sinha; Alec A Schmaier; Dongxiao Shen; Yan Gao; Michael E Hall; Adolfo Correa; Russell P Tracy; Peter Durda; Kent D Taylor; Yongmei Liu; W Craig Johnson; Xiuqing Guo; Jie Yao; Yii-Der Ida Chen; Ani W Manichaikul; Deepti Jain; Claude Bouchard; Mark A Sarzynski; Stephen S Rich; Jerome I Rotter; Thomas J Wang; James G Wilson; Pradeep Natarajan; Robert E Gerszten Journal: Circulation Date: 2021-11-24 Impact factor: 39.918
Authors: Richard G Jung; Pouya Motazedian; F Daniel Ramirez; Trevor Simard; Pietro Di Santo; Sarah Visintini; Mohammad Ali Faraz; Alisha Labinaz; Young Jung; Benjamin Hibbert Journal: Thromb J Date: 2018-06-05
Authors: Nikolai N Potekaev; Olga B Borzykh; German V Medvedev; Denis V Pushkin; Marina M Petrova; Artem V Petrov; Diana V Dmitrenko; Elena I Karpova; Olga M Demina; Natalia A Shnayder Journal: J Clin Med Date: 2021-12-18 Impact factor: 4.241